LLY
Lilly’s oncology side quest is looking more like a main storyline
Eli Lilly just dropped a pretty useful piece of news for Jaypirca, its leukemia drug. In the Phase 3 BRUIN CLL-322 trial, adding pirtobrutinib to venetoclax and rituximab beat venetoclax and rituximab alone on progression-free survival in relapsed or refractory CLL/SLL.
The headline stat? The combo cut the risk of disease progression or death by 45%. In biotech land, that’s the sort of number that can turn a “maybe” into a “let’s talk to regulators.”
Why investors should care
Lilly said the data support plans to submit the results to global regulators in hopes of expanding Jaypirca’s label. That matters because a broader label usually means a bigger addressable market, more physician adoption, and fewer “this is only for that very specific patient group” headaches.
A few nuggets from the readout:
- The study enrolled 639 patients with relapsed or refractory CLL/SLL
- Nearly 80% had previously received a covalent BTK inhibitor
- Median progression-free survival was not reached in the Jaypirca combo arm, versus 39.7 months in the control arm
- The benefit showed up across higher-risk subgroups too, which is exactly the kind of thing drugmakers like to brag about at conferences
The next stop: the regulators
Lilly says it’ll present the findings at the European Hematology Association meeting and then hand the package to regulators. So this isn’t cash-in-the-pockets revenue yet — but it is the kind of clinical data that can move the story from “pipeline promise” to “commercial opportunity.”
Big picture: Lilly’s been known lately for weight-loss fireworks, but this is a reminder that its oncology arm can still throw a punch too.